Archives
-
Drug Repurposing for CRISPR DNA Repair Pathway Choice
2026-10-07
The reference study presents a large-scale screen of clinically approved drugs for their ability to shift DNA double-strand break repair outcomes in human induced pluripotent stem cells. Its findings connect pharmacological perturbation with NHEJ, MMEJ, HDR, and synthetic lethality, while also identifying ESR2 and AOX1 as candidate regulators of repair-pathway behavior.
-
Firefly Luciferase mRNA: Evidence and Limits
2026-10-07
Firefly Luciferase mRNA is a useful reporter for studying expression and delivery, but catalog claims about 5-moUTP chemistry should not be treated as direct evidence for every formulation. This overview compares supplier information with recent peer-reviewed findings on RNA nanoparticle delivery, emphasizing interpretation, provenance, applicability boundaries, and key limitations.
-
SB743921 and Translational Mitotic Drug Response
2026-10-06
A source-grounded perspective on how SB743921 can sharpen mechanistic and translational interpretation of mitotic drug responses in cancer research.
-
Latrunculin B: Interpreting Actin-Pathway Evidence
2026-10-06
Latrunculin B is more than an actin polymerization inhibitor: it is a tool for distinguishing cytoskeletal involvement from pathway-specific causality. This evidence-led analysis examines the GCRV entry study, explains its negative latrunculin B result, and defines the compound’s interpretation boundaries.
-
PA-824 in Tuberculosis Research: Mechanism and Evidence
2026-10-05
A source-grounded overview of PA-824, also known as pretomanid in the research literature, covering its proposed dual activity, respiratory effects, conceptual applications, combination evidence, and important limits on interpretation.
-
N2703 and Nicotine Biosynthesis: Five Key Questions
2026-10-05
A source-grounded overview of 3-(1-methylpyrrolidin-2-yl)pyridine (N2703), the 2026 nicotine-biosynthesis study, the strength of its evidence, and the limits of applying plant-pathway findings to biomedical signaling research.
-
How Pretomanid Targets TB Terminal Oxidases
2026-10-04
The reference study identifies simultaneous inhibition of the cytochrome bcc:aa3 and cytochrome bd respiratory branches as a central feature of pretomanid activity against Mycobacterium tuberculosis. Its findings support rational combinations with terminal-oxidase inhibitors to improve bactericidal activity and constrain resistance, while remaining primarily preclinical evidence.
-
Nirmatrelvir: From 3CL Protease to Translation
2026-10-03
Nirmatrelvir (PF-07321332) illustrates how a validated viral protease target can connect structural biology, antiviral therapeutics research, and translational strategy. This analysis separates mechanistic rationale from computational evidence and outlines the questions that matter beyond a typical product page.
-
From circ-ECH1 to BPD: Building Trustworthy qRT-PCR
2026-10-02
A translational perspective on how assay design and engineered reverse-transcription chemistry can strengthen circ-ECH1, miR-708-5p, and Ntrk2 research in bronchopulmonary dysplasia. The article connects findings from a hyperoxia model with practical strategies for reproducible cDNA synthesis, low-input RNA workflows, and appropriately cautious biomarker development.
-
HOBt (1-Hydroxybenzotriazole) for Reliable Workflows
2026-10-01
This scenario-driven guide explains where HOBt (1-Hydroxybenzotriazole), SKU A7025, can improve upstream peptide and small-molecule synthesis without being mistaken for a cell-viability assay reagent. It connects coupling chemistry, stereochemical control, product selection, and assay interpretation using product specifications and published glucagon receptor antagonist research.
-
Mitoxantrone HCl: From DNA Damage to ERα Assays
2026-10-01
Mitoxantrone HCl is more than a DNA topoisomerase II inhibitor: emerging evidence shows that it can also disrupt ERα through an allosteric DBD–LBD interface. This article presents an assay-centered framework for separating DNA damage, receptor degradation, apoptosis, and viability effects.
-
Dantrolene Sodium Salt: RyR Workflow Guide
2026-09-30
Build controlled calcium-release experiments with Dantrolene sodium salt, a potent ryanodine receptor antagonist suited to cardiomyocyte, pancreatitis, neurodegeneration, and ischemia models. This guide also shows how to add calcium-state controls to CRISPR DNA-repair assays without overstating evidence for a direct genome-editing mechanism.
-
N2703: Applied Workflows for Cellular Signaling
2026-09-30
Use 3-(1-methylpyrrolidin-2-yl)pyridine (N2703) as a controlled chemical probe for cellular signaling, pathway-response assays, and nicotine-biosynthesis research. This guide emphasizes concentration control, orthogonal readouts, metabolon-informed experiments, and troubleshooting rather than assuming an unvalidated target mechanism.
-
In Vitro Cancer Drug Response: Growth vs Death
2026-09-29
Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is a time-aware framework that separates proliferative arrest from cell killing, improving interpretation of drug-response experiments and the design of follow-up assays.
-
HyperScript RT SuperMix for qPCR in Exosomes
2026-09-29
HyperScript RT SuperMix for qPCR can strengthen the mRNA arm of exosomal miRNA studies by supporting consistent cDNA synthesis from difficult RNA inputs. This article explains how to match reverse-transcription chemistry to RNA class, sample quality, and mechanistic assay design in sepsis-related lung injury research.